Photo of Manuel Hidalgo,  MD, PhD

Manuel Hidalgo, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-0542
Fax: (617) 667-3915

Manuel Hidalgo, MD, PhD

Beth Israel Deaconess Medical Center


  • Professor, Medicine, Harvard Medical School
  • Chief, Hematology Oncology, Beth Israel Deaconess Medical Center
  • Director, Rosenberg Clinical Cancer Center, Beth Israel Deaconess Medical Center
  • Co-Director, Pancreatic Cancer Research Program, Beth Israel Deaconess Medical Center



  • Deputy Associate Director, Clinical Science, Executive Committee
  • Member, Center Scientific Council

Research Abstract

My research interest have centered in translational and clinical research in anticancer drug development with a particular emphasis in pancreatic cancer. We have led the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer. Our most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalizes medicine in PDAC. About 15 years ago we initiated the development of patient derived xenograft models of pancreas cancer as a platform for translational studies in this disease. Using a well-characterized PDX models we identified nab-paclitaxel activity in pancreas cancer, a work than paved the way for clinical studies that eventually led to the approval of the drug. More recently we have identified demcizumab and palbociclib that are now in early clinical development as well. I am also using this approach in a multicenter study named AVATAR that aims to use mouse model for personalize medicine approaches. Our immediate goal now is to incorporate immune treatment approaches both in preclinical models and in clinical studies in pancreas cancer. The National Cancer Institute has funded my research and I have been the recipient of a European Research Council advanced grant as well.


Powered by Harvard Catalyst
  • Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br J Cancer 2018; 119:1471-1476. PubMed
  • Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart D, Moutouh-de Parseval L, Demuth T, Dummer R. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clin Cancer Res 2017. PubMed
  • Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Stu J Clin Oncol 2016; 35:157-165. PubMed
  • Von Hoff D, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE,Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T,,Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial J Clin Oncol 2011.